- Home
- CAN vs AVIR Comparison
CAN vs AVIR Comparison
Compare CAN & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAN | AVIR |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.2M | 236.7M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CAN | AVIR |
|---|---|---|
| Price | $0.76 | $3.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 1 |
| Target Price | $3.56 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 19.5M | 371.5K |
| Earning Date | 11-18-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $422,228,000.00 | N/A |
| Revenue This Year | $92.55 | N/A |
| Revenue Next Year | $41.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 83.87 | N/A |
| 52 Week Low | $0.53 | $2.46 |
| 52 Week High | $2.47 | $4.02 |
Technical Indicators
Market Signals| Indicator | CAN | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 71.27 |
| Support Level | $0.77 | $3.11 |
| Resistance Level | $0.89 | $3.72 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 16.65 | 90.24 |
Price Performance
Historical ComparisonAbout CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).